Literature DB >> 35442085

Tumor Vascular Remodeling Affects Molecular Dissemination to Lymph Node and Systemic Leukocytes.

Meghan J O'Melia1, Nathan A Rohner2,3, Susan Napier Thomas1,2,3,4.   

Abstract

Angiogenic and lymphangiogenic remodeling has long been accepted as a hallmark of cancer development and progression; however, the impacts of this remodeling on immunological responses, which are paramount to the responses to immunotherapeutic treatments, are underexplored. As immunotherapies represent one of the most promising new classes of cancer therapy, in this study, we explore the effects of angiogenic and lymphangiogenic normalization on dissemination of molecules injected into the tumor microenvironment to immune cells in lymph nodes draining the tumor as well as in systemically distributed tissues. A system of fluorescent tracers, size-matched to biomolecules of interest, was implemented to track different mechanisms of tumor transport and access to immune cells. This revealed that the presence of a tumor, and either angiogenic or lymphangiogenic remodeling, altered local retention of model biomolecules, trended toward normalizing dissemination to systemic organs, and modified access to lymph node-resident immune cells in manners dependent on mechanism of transport. More specifically, active cell migration by skin-derived antigen presenting cells was enhanced by both the presence of a tumor and lymphangiogenic normalization, while both angiogenic and lymphangiogenic normalization restored patterns of immune cell access to passively draining species. As a whole, this work uncovers the potential ramifications of tumor-induced angiogenesis and lymphangiogenesis, along with impacts of interrogation into these pathways, on access of tumor-derived species to immune cells. Impact Statement Angiogenic and lymphangiogenic normalization strategies have been utilized clinically to interrogate tumor vasculature with some success. In the age of immunotherapy, the impacts of these therapeutic interventions on immune remodeling are unclear. This work utilizes mouse models of angiogenic and lymphangiogenic normalization, along with a system of fluorescently tagged tracers, to uncover the impacts of angiogenesis and lymphangiogenesis on access of tumor-derived species to immune cell subsets within various organs.

Entities:  

Keywords:  angiogenic normalization; biodistribution; growth factor; immune remodeling; lymphangiogenesis; tissue engineering

Mesh:

Year:  2022        PMID: 35442085      PMCID: PMC9508451          DOI: 10.1089/ten.TEA.2022.0020

Source DB:  PubMed          Journal:  Tissue Eng Part A        ISSN: 1937-3341            Impact factor:   4.080


  63 in total

Review 1.  Implications of Lymphatic Transport to Lymph Nodes in Immunity and Immunotherapy.

Authors:  Susan N Thomas; Nathan A Rohner; Erin E Edwards
Journal:  Annu Rev Biomed Eng       Date:  2016-02-24       Impact factor: 9.590

2.  Steady-state antigen scavenging, cross-presentation, and CD8+ T cell priming: a new role for lymphatic endothelial cells.

Authors:  Sachiko Hirosue; Efthymia Vokali; Vidya R Raghavan; Marcela Rincon-Restrepo; Amanda W Lund; Patricia Corthésy-Henrioud; Francesca Capotosti; Cornelia Halin Winter; Stéphanie Hugues; Melody A Swartz
Journal:  J Immunol       Date:  2014-05-02       Impact factor: 5.422

3.  SU11248, a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells.

Authors:  Emily Young; Lucio Miele; Kevan B Tucker; Min Huang; Jeremy Wells; Jian-Wei Gu
Journal:  Cancer Biol Ther       Date:  2010-10-01       Impact factor: 4.742

4.  Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.

Authors:  Janis M Taube; Alison Klein; Julie R Brahmer; Haiying Xu; Xiaoyu Pan; Jung H Kim; Lieping Chen; Drew M Pardoll; Suzanne L Topalian; Robert A Anders
Journal:  Clin Cancer Res       Date:  2014-04-08       Impact factor: 12.531

5.  Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival.

Authors:  Soheil S Dadras; Thomas Paul; Jennifer Bertoncini; Lawrence F Brown; Alona Muzikansky; David G Jackson; Ulf Ellwanger; Claus Garbe; Martin C Mihm; Michael Detmar
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

6.  Quantitation of lymphatic transport mechanism and barrier influences on lymph node-resident leukocyte access to lymph-borne macromolecules and drug delivery systems.

Authors:  Paul A Archer; Lauren F Sestito; Margaret P Manspeaker; Meghan J O'Melia; Nathan A Rohner; Alex Schudel; Yajun Mei; Susan N Thomas
Journal:  Drug Deliv Transl Res       Date:  2021-06-24       Impact factor: 4.617

7.  Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC.

Authors:  Meghan J O'Melia; Margaret P Manspeaker; Susan N Thomas
Journal:  Cancer Immunol Immunother       Date:  2021-01-18       Impact factor: 6.630

8.  Tumor-Associated Lymphatic Vessels Upregulate PDL1 to Inhibit T-Cell Activation.

Authors:  Lothar C Dieterich; Kristian Ikenberg; Timur Cetintas; Kübra Kapaklikaya; Cornelia Hutmacher; Michael Detmar
Journal:  Front Immunol       Date:  2017-02-03       Impact factor: 7.561

9.  Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.

Authors:  H Wildiers; G Guetens; G De Boeck; E Verbeken; B Landuyt; W Landuyt; E A de Bruijn; A T van Oosterom
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

Review 10.  Factors involved in cancer metastasis: a better understanding to "seed and soil" hypothesis.

Authors:  Qiang Liu; Hongfei Zhang; Xiaoli Jiang; Caiyun Qian; Zhuoqi Liu; Daya Luo
Journal:  Mol Cancer       Date:  2017-12-02       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.